Cargando…

Sulfasalazine Microparticles Targeting Macrophages for the Treatment of Inflammatory Diseases Affecting the Synovial Cavity

Rheumatoid arthritis (RA) is a chronic inflammatory disease with sulfasalazine (SSZ) extensively used for long-term treatment of both juvenile and adult RA. Its use is associated with adverse effects and toxicity due to its non-selective biodistribution. Macrophages play an important role in inflamm...

Descripción completa

Detalles Bibliográficos
Autores principales: Villa-Hermosilla, Monica-Carolina, Fernández-Carballido, Ana, Hurtado, Carolina, Barcia, Emilia, Montejo, Consuelo, Alonso, Mario, Negro, Sofia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8309090/
https://www.ncbi.nlm.nih.gov/pubmed/34202859
http://dx.doi.org/10.3390/pharmaceutics13070951
_version_ 1783728439116693504
author Villa-Hermosilla, Monica-Carolina
Fernández-Carballido, Ana
Hurtado, Carolina
Barcia, Emilia
Montejo, Consuelo
Alonso, Mario
Negro, Sofia
author_facet Villa-Hermosilla, Monica-Carolina
Fernández-Carballido, Ana
Hurtado, Carolina
Barcia, Emilia
Montejo, Consuelo
Alonso, Mario
Negro, Sofia
author_sort Villa-Hermosilla, Monica-Carolina
collection PubMed
description Rheumatoid arthritis (RA) is a chronic inflammatory disease with sulfasalazine (SSZ) extensively used for long-term treatment of both juvenile and adult RA. Its use is associated with adverse effects and toxicity due to its non-selective biodistribution. Macrophages play an important role in inflammatory processes. In order to target SSZ to macrophages in this work two microparticulate systems (MPs) are developed: SSZ-loaded PLGA MPs without and with α-tocopherol, with particle sizes lower than 5 μm and encapsulation efficiencies of 81.07 ± 11% and 63.50 ± 6.62%, respectively. Release of SSZ from MPs prepared with α-tocopherol was prolonged for 20 days. In RAW 264.7 cell macrophages MPs prepared with α-tocopherol were captured faster. Cell viability studies confirmed that SSZ-loaded MPs prepared without and with α-tocopherol did not produce cytotoxicity at the concentrations assayed. The anti-inflammatory activity of SSZ-loaded MPs was studied by quantifying interleukins IL-1, IL-6 and TNF-α in macrophages. All formulations produced a significant reduction of cytokine concentrations after 24 and 72 h, indicating that release of SSZ from the MPs was able to inhibit the inflammatory response induced by lipopolysaccharide (LPS). Gene expression of IL-1, IL-6 and TNF-α was decreased by SSZ-loaded MPs. SSZ-loaded MPs prepared with α-tocopherol will potentially allow increasing the residence time of SSZ in the synovial cavity, prolonging its duration of action, and reducing the adverse effects associated with its non-selective biodistribution.
format Online
Article
Text
id pubmed-8309090
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-83090902021-07-25 Sulfasalazine Microparticles Targeting Macrophages for the Treatment of Inflammatory Diseases Affecting the Synovial Cavity Villa-Hermosilla, Monica-Carolina Fernández-Carballido, Ana Hurtado, Carolina Barcia, Emilia Montejo, Consuelo Alonso, Mario Negro, Sofia Pharmaceutics Article Rheumatoid arthritis (RA) is a chronic inflammatory disease with sulfasalazine (SSZ) extensively used for long-term treatment of both juvenile and adult RA. Its use is associated with adverse effects and toxicity due to its non-selective biodistribution. Macrophages play an important role in inflammatory processes. In order to target SSZ to macrophages in this work two microparticulate systems (MPs) are developed: SSZ-loaded PLGA MPs without and with α-tocopherol, with particle sizes lower than 5 μm and encapsulation efficiencies of 81.07 ± 11% and 63.50 ± 6.62%, respectively. Release of SSZ from MPs prepared with α-tocopherol was prolonged for 20 days. In RAW 264.7 cell macrophages MPs prepared with α-tocopherol were captured faster. Cell viability studies confirmed that SSZ-loaded MPs prepared without and with α-tocopherol did not produce cytotoxicity at the concentrations assayed. The anti-inflammatory activity of SSZ-loaded MPs was studied by quantifying interleukins IL-1, IL-6 and TNF-α in macrophages. All formulations produced a significant reduction of cytokine concentrations after 24 and 72 h, indicating that release of SSZ from the MPs was able to inhibit the inflammatory response induced by lipopolysaccharide (LPS). Gene expression of IL-1, IL-6 and TNF-α was decreased by SSZ-loaded MPs. SSZ-loaded MPs prepared with α-tocopherol will potentially allow increasing the residence time of SSZ in the synovial cavity, prolonging its duration of action, and reducing the adverse effects associated with its non-selective biodistribution. MDPI 2021-06-24 /pmc/articles/PMC8309090/ /pubmed/34202859 http://dx.doi.org/10.3390/pharmaceutics13070951 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Villa-Hermosilla, Monica-Carolina
Fernández-Carballido, Ana
Hurtado, Carolina
Barcia, Emilia
Montejo, Consuelo
Alonso, Mario
Negro, Sofia
Sulfasalazine Microparticles Targeting Macrophages for the Treatment of Inflammatory Diseases Affecting the Synovial Cavity
title Sulfasalazine Microparticles Targeting Macrophages for the Treatment of Inflammatory Diseases Affecting the Synovial Cavity
title_full Sulfasalazine Microparticles Targeting Macrophages for the Treatment of Inflammatory Diseases Affecting the Synovial Cavity
title_fullStr Sulfasalazine Microparticles Targeting Macrophages for the Treatment of Inflammatory Diseases Affecting the Synovial Cavity
title_full_unstemmed Sulfasalazine Microparticles Targeting Macrophages for the Treatment of Inflammatory Diseases Affecting the Synovial Cavity
title_short Sulfasalazine Microparticles Targeting Macrophages for the Treatment of Inflammatory Diseases Affecting the Synovial Cavity
title_sort sulfasalazine microparticles targeting macrophages for the treatment of inflammatory diseases affecting the synovial cavity
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8309090/
https://www.ncbi.nlm.nih.gov/pubmed/34202859
http://dx.doi.org/10.3390/pharmaceutics13070951
work_keys_str_mv AT villahermosillamonicacarolina sulfasalazinemicroparticlestargetingmacrophagesforthetreatmentofinflammatorydiseasesaffectingthesynovialcavity
AT fernandezcarballidoana sulfasalazinemicroparticlestargetingmacrophagesforthetreatmentofinflammatorydiseasesaffectingthesynovialcavity
AT hurtadocarolina sulfasalazinemicroparticlestargetingmacrophagesforthetreatmentofinflammatorydiseasesaffectingthesynovialcavity
AT barciaemilia sulfasalazinemicroparticlestargetingmacrophagesforthetreatmentofinflammatorydiseasesaffectingthesynovialcavity
AT montejoconsuelo sulfasalazinemicroparticlestargetingmacrophagesforthetreatmentofinflammatorydiseasesaffectingthesynovialcavity
AT alonsomario sulfasalazinemicroparticlestargetingmacrophagesforthetreatmentofinflammatorydiseasesaffectingthesynovialcavity
AT negrosofia sulfasalazinemicroparticlestargetingmacrophagesforthetreatmentofinflammatorydiseasesaffectingthesynovialcavity